SME info day - navigating EMA support: From development to market authorisation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 6 November 2026, 09:15 (CET) to 6 November 2026, 16:00 (CET)

Submitted by Anonymous (not verified) on 13 July 2026 - 16:33

SME info day - navigating EMA support: From development to market authorisation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 6 November 2026, 09:15 (CET) to 6 November 2026, 16:00 (CET)

Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 13 July 2026 - 16:25

Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Revision: 6, Status: Authorised

Joint response from European Medicines Regulatory Network to letter from Health Action International and other health groups on missing clinical trial results in CTIS

Submitted by Anonymous (not verified) on 13 July 2026 - 15:54

Joint response from European Medicines Regulatory Network to letter from Health Action International and other health groups on missing clinical trial results in CTIS

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 10, Status: Authorised

Submitted by Anonymous (not verified) on 13 July 2026 - 15:52

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 10, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness